Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers ...

Fragile X disorders include two distinct conditions: fragile X syndrome (the most common single-gene cause of developmental ...

An experimental mRNA vaccine has boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to ...

How does a cell know when it’s been damaged? A molecular alarm, set off by mutated RNA and colliding ribosomes, signals ...

The genetic information is transcribed and subsequently translated into functional proteins. ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Study reveals how cells regulate repair protein production to prevent DNA damage over-repair or under-repair, aiding cell ...

Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the ...